Predictors of Development of Diabetes in Patients With Chronic Heart Failure in the Candesartan in Heart Failure Assessment of Reduction in Mortality and Morbidity (CHARM) Program

OBJECTIVE The purpose of this study was to identify predictors of incident diabetes during follow-up of nondiabetic patients with chronic heart failure (CHF) in the Candesartan in Heart Failure Assessment of Reduction in Mortality and Morbidity (CHARM) program. RESEARCH DESIGN AND METHODS A total of 1,620 nondiabetic patients had full baseline datasets. We compared baseline demographic, medication, and laboratory data for patients who did or did not develop diabetes and conducted logistic regression and receiver operator characteristic curve analyses. RESULTS Over a median period of 2.8 years, 126 of the 1,620 patients (7.8%) developed diabetes. In multiple logistic regression analysis, the following baseline characteristics were independently associated with incident diabetes in decreasing order of significance by stepwise selection: higher A1C (odds ratio [OR] 1.78 per 1 SD increase; P < 0.0001), higher BMI (OR 1.64 per 1 SD increase; P < 0.0001), lipid-lowering therapy (OR 2.05; P = 0.0005), lower serum creatinine concentration (OR 0.68 per 1 SD increase; P = 0.0018), diuretic therapy (OR 4.81; P = 0.003), digoxin therapy (OR 1.65; P = 0.022), higher serum alanine aminotransferase concentration (OR 1.15 per 1 SD increase; P = 0.027), and lower age (OR 0.81 per 1 SD increase; P = 0.048). Using receiver operating characteristic curve analysis, A1C and BMI yielded areas under the curve of 0.723 and 0.712, respectively, increasing to 0.788 when combined. Addition of other variables independently associated with diabetes risk minimally improved prediction of diabetes. CONCLUSIONS In nondiabetic patients with CHF in CHARM, A1C and BMI were the strongest predictors of the development of diabetes. Other minor predictors in part reflected CHF severity or drug-associated diabetes risk. Identifying patients with CHF at risk of diabetes through simple criteria appears possible and could enable targeted preventative measures.

[1]  N. Sattar,et al.  Non-alcoholic fatty liver disease: an overview of prevalence, diagnosis, pathogenesis and treatment considerations. , 2008, Clinical science.

[2]  David B Sacks,et al.  A new look at screening and diagnosing diabetes mellitus. , 2008, The Journal of clinical endocrinology and metabolism.

[3]  Karl Swedberg,et al.  Impact of diabetes on outcomes in patients with low and preserved ejection fraction heart failure: an analysis of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programme. , 2008, European heart journal.

[4]  R. McKelvie,et al.  Diabetes, left ventricular systolic dysfunction, and chronic heart failure. , 2008, European heart journal.

[5]  A. Chetrit,et al.  Predicting the 20‐year diabetes incidence rate , 2007, Diabetes/metabolism research and reviews.

[6]  P. Ridker,et al.  Hemoglobin A1c predicts diabetes but not cardiovascular disease in nondiabetic women. , 2007, The American journal of medicine.

[7]  M. Kubo,et al.  Liver Enzymes as a Predictor for Incident Diabetes in a Japanese Population: The Hisayama Study , 2007, Obesity.

[8]  S. Yusuf,et al.  Glucose Levels Predict Hospitalization for Congestive Heart Failure in Patients at High Cardiovascular Risk , 2007, Circulation.

[9]  W. Elliott,et al.  Incident diabetes in clinical trials of antihypertensive drugs: a network meta-analysis , 2007, The Lancet.

[10]  L. Weinehall,et al.  A combination of HbA1c, fasting glucose and BMI is effective in screening for individuals at risk of future type 2 diabetes: OGTT is not needed , 2006, Journal of internal medicine.

[11]  M. Engelgau,et al.  Changes in incidence of diabetes in U.S. adults, 1997-2003. , 2006, American journal of preventive medicine.

[12]  M. Pfeffer,et al.  Effects of Candesartan on the Development of a New Diagnosis of Diabetes Mellitus in Patients With Heart Failure , 2005, Circulation.

[13]  P. Macfarlane,et al.  Elevated alanine aminotransferase predicts new-onset type 2 diabetes independently of classical risk factors, metabolic syndrome, and C-reactive protein in the west of Scotland coronary prevention study. , 2004, Diabetes.

[14]  B. Bradbury,et al.  Statins and newly diagnosed diabetes. , 2004, British journal of clinical pharmacology.

[15]  C. Gullion,et al.  The incidence of congestive heart failure in type 2 diabetes: an update. , 2004, Diabetes care.

[16]  W. Knowler,et al.  Glycated haemoglobin predicts progression to diabetes mellitus in Pima Indians with impaired glucose tolerance , 1994, Diabetologia.

[17]  David Bell,et al.  Functional class in patients with heart failure is associated with the development of diabetes. , 2003, The American journal of medicine.

[18]  Karl Swedberg,et al.  Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial , 2003, The Lancet.

[19]  Karl Swedberg,et al.  Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial , 2003, The Lancet.

[20]  M. Pfeffer,et al.  Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial , 2003, The Lancet.

[21]  M. Pfeffer,et al.  Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme , 2003, The Lancet.

[22]  A. Gaw,et al.  The Anatomy of a Clinical Trial , 2002, Medical Principles and Practice.

[23]  J. Pankow,et al.  Sensitivity and specificity of anthropometrics for the prediction of diabetes in a biracial cohort. , 2001, Obesity research.

[24]  N. Wareham,et al.  Diabetes risk score: towards earlier detection of Type 2 diabetes in general practice , 2000, Diabetes/metabolism research and reviews.

[25]  G. Paolisso,et al.  Congestive heart failure predicts the development of non-insulin-dependent diabetes mellitus in the elderly. The Osservatorio Geriatrico Regione Campania Group. , 1997, Diabetes & metabolism.